Standout Papers

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastati... 2023 2026 2024177
  1. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial (2023)
    Hope S. Rugo, Aditya Bardia et al. The Lancet

Immediate Impact

9 standout
Sub-graph 1 of 5

Citing Papers

Advances in targeting histone deacetylase for treatment of solid tumors
2024 Standout
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
1 intermediate paper

Works of Peter Schmid being referenced

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)
2023

Author Peers

Author Last Decade Papers Cites
Peter Schmid 191 105 45 58 11 224
T. Valdez 234 141 61 73 16 275
Mariela Blum‐Murphy 133 95 43 41 9 227
Daniel Barrios 207 92 23 84 12 254
Q. Hong 192 95 26 49 8 233
Míriam Arumí 112 79 47 37 12 169
Mojca Unk 132 114 23 65 14 187
Eileen Wrabel 214 53 71 139 13 267
Elisa Minenza 177 115 31 32 12 240
Marcelle Goldner Cesca 216 74 95 87 17 259
Larry Schlabach 181 147 26 27 10 295

All Works

Loading papers...

Rankless by CCL
2026